Karo Healthcare AB (“Karo”) has entered an exclusive licensing agreement with Moberg Pharma AB (“Moberg Pharma”) regarding the commercialisation of MOB-015 in Europe. The agreement comprises 19 European markets, enabling...
Karo Healthcare (“Karo”) has appointed Konstanze Gallinatus as Chief Transformation Officer and member of the Corporate Management Team. The appointment of Konstanze reflects Karo’s significant growth ambitions in the years...
Following the closing of KKR’s acquisition of Karo Healthcare (“Karo”) on 27 August, Karo today confirms that the agreement to acquire a portfolio of skin health brands, including ACO, has been transferred to Karo. The pending transaction was previously announced by a KKR-affiliated vehicle and Perrigo Company plc (“Perrigo”) on 14 July, 2025, and the terms remain unchanged with the transaction expected to close in Q1 2026. Perrigo’s Dermacosmetics branded business, which generated more than EUR 120 million in net sales in 2024 across the Nordics, the Netherlands, and Poland, includes trusted, science-backed skincare brands and has a strong strategic fit with Karo’s business.
Today, on 15 April 2025, Karo Group* is publishing its 2024 Sustainability Report on the company’s website, www.karohealthcare.com. For further information, please contact: Christoffer Lorenzen, CEO, +46 735 017 620,...
Karo Healthcare (“Karo”) will change owner following the announcement that EQT has agreed to sell Karo to funds managed by KKR, a leading global investment firm. The transaction marks a...
